Clinical and pharmacogenetic study of Attention-Deficit/Hyperactivity disorder (ADHD)

Principal Investigator: 

Natalie Grizenko, MD, Ridha Joober, MD, PhD.

Description of the study: 

Our team of researchers specializing in the field of ADHD includes child psychiatrists, psychologists and a psychiatric geneticist, and explores the causes of ADHD in children, in order to develop better treatments.

Financial compensation: 
no
Functionning: 
  1. If the child agrees to participate, he or she will be asked to answer academic-type questions and perform tests on a computer (e.g. push a button) to a specific signal or sorting cards.
  2. He or she will be given 0.5 mg/kg of Ritalin for one week and a placebo (a pill that looks exactly like the real medication, but does not contain medication) for another week.
  3. In order to study the genetics of ADHD, a blood test will be taken on one occasion.

Parents are asked for information about family history and symptoms of the child, including symptoms that occurred before and during birth. They are asked to give a single blood sample for genetic purposes.

During the study, parents answer questions about the child on three occasions, approximately one week apart.

Benefits: 
  1. Your child will receive a full psychological and intellectual assessment.
  2. Your child will receive a comprehensive clinical evaluation to assess whether, and to what extent, your child's behaviour improves with Ritalin.
  3. The results of these evaluations will be available to you.
  4. All evaluations and medications are free of charge.
Eligibility criteria: 

Children 6 to 12 years of age, diagnosed with ADHD.

Information: 

To participate in the study, please contact :

Marina Ter-stepanian
Study Coordinator

Tel. : 514-761-6131 ext. 3115
marina.terstepanian@douglas.mcgill.ca


McGill Logo

CIUSSS ouest montreal logo

 



  • Douglas Hospital
  • Dobell Pavillion
  • Brain imaging centre